Elutia (Elutia) Change In Working Capital : $6.96 Mil (TTM As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Elutia Change In Working Capital?

Elutia's change in working capital for the quarter that ended in Dec. 2023 was $0.27 Mil.

Elutia's change in working capital for the fiscal year that ended in Dec. 2023 was $6.96 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Elutia Change In Working Capital Historical Data

The historical data trend for Elutia's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Elutia Change In Working Capital Chart

Elutia Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-0.47

-2.67

2.38

5.71

6.96

Elutia Quarterly Data
	Dec18	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															2.47	0.33	2.90	3.46	0.27

Elutia Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $6.96 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Elutia Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Elutia's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Elutia (Elutia) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Elutia Inc (NAS:ELUT) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

12510 Prosperity Drive, Suite 370, Silver Spring, MD, USA, 20904

Website

https://www.aziyo.com

Elutia Inc Formerly Aziyo Biologics Inc is a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, concentrating on patients receiving implantable medical devices. The company's segments include Device Protection, Women's Health, Orthobiologics, and Cardiovascular. It generates maximum revenue from the Orthobiologics segment. The products of the company are targeted to address unmet clinical needs with the goal of promoting healthy tissue formation and avoiding complications associated with medical device implants, such as scar-tissue formation, capsular contraction, erosion, migration, non-union of implants and implant rejection.

Executives

Elutia Pipe Investment, Lp	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Birchview Fund Llc	10 percent owner	688 PINE STREET, BURLINGTON VT 05401
Thomas Englese	officer: Chief Commercial Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRING MD 20904
David Colpman	director	452 FIFTH AVENUE, NEW YORK NY 10018
Brigid Makes	director	20245 SW 95TH AVENUE, TUALATIN OR 97062
Matthew Ferguson	officer: Chief Financial Officer	C/O FOXHOLLOW TECHNOLOGIES, INC., 740 BAY ROAD, REDWOOD CITY CA 94063
Highcape Partners Gp Ii, Llc	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Gp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Qp Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Partners Ii, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Highcape Capital, L.p.	10 percent owner	36 CHURCH LANE, WESTPORT CT 06880
Michelle Leroux Williams	officer: Chief Scientific Officer	C/O AZIYO BIOLOGICS, INC., 12510 PROSPERITY DRIVE, SUITE 370, SILVER SPRINT MD 20904
Matthew Strobeck	10 percent owner	C/O METABOLIX, INC., 21 ERIE STREET, CAMBRIDGE MA 02139
Birchview Capital, Lp	10 percent owner	688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON VT 05401
Peter G Edwards	officer: GENERAL COUNSEL	C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015